ArticleBMC medical imaging2026
Intratumoral and peritumoral habitat imaging based on multiparametric MRI to predict HER2-negative breast cancer subtypes: a multicenter study.
Article in BMC medical imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHER2 expression status reflects the heterogeneity of breast cancer and is closely associated with variations in the tumor microenvironment. Noninvasive imaging approaches capable of capturing this spatial heterogeneity may improve subtype stratification in HER2-negative breast cancer. PURPOSE: The aim of this study was to develop a global tumor habitat model combining habitat signatures derived from multiparametric MRI (mpMRI) with intratumoral and peritumoral radiomic features, and to evaluate its feasibility for predicting subtypes of HER2-negative breast cancer.
methodsIn this multicenter retrospective analysis, 432 patients diagnosed with breast cancer were divided into training (n = 259), validation (n = 112), and test (n = 61) cohorts. Each voxel within the annotated region of interest (ROI) from both dynamic contrast-enhanced (DCE) and T2-weighted image (T2WI) sequences was characterized using a set of localized features. Voxel-wise feature vectors were subsequently clustered via the K-means algorithm to partition tumor ROIs into morphologically distinct subregions. Peritumoral regions were generated by radial expansion of the original ROI by 3 and 5 mm. Independent machine learning models were developed for intratumoral radiomics, peritumoral (PeriXmm), habitat (Habitat, HabitatT2, HabitatDCE), and clinical signatures. A combined predictive model integrating the optimal peritumoral features, habitat-derived signatures, and clinical parameters was constructed.
resultsCompared with the intratumoral radiomics model, the habitat model demonstrated superior predictive performance across all cohorts, with area under the ROC curve (AUC) values of 0.890, 0.841, and 0.820 in the training, validation, and test cohorts, respectively, versus 0.839, 0.723, and 0.639 for the intratumoral model. The Peri3mm model provided a more reliable representation of the peritumoral microenvironment than the Peri5mm model across external cohorts (AUC: 0.749 vs. 0.735). The combined model achieved the highest predictive overall performance, with AUCs of 0.906, 0.899, and 0.824.
conclusionThe combined intratumoral-peritumoral habitat-based model demonstrated the most robust and generalizable performance in the accurate and noninvasive prediction of HER2-negative breast cancer subtypes across multicenter cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.